Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sertraline** is a selective serotonin reuptake inhibitor (*SSRI*) antidepressant used to treat major depressive disorder; obsessive-compulsive disorder; panic disorder; post-traumatic stress disorder; social anxiety disorder; and premenstrual dysphoric disorder. It works primarily by inhibiting the serotonin transporter (*SERT*), increasing levels of serotonin in the brain and thereby improving mood and emotional balance. Secondary pharmacological actions include weak inhibition of the dopamine transporter (*DAT*) at higher doses and antagonism at sigma-1 receptors. The original developer was Pfizer[2][7]. The drug is widely prescribed due to its efficacy and relatively favorable side effect profile compared to older antidepressants[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sertraline.